Allscripts-Misys Healthcare Solutions Inc. (MDRX) recently launched two new products − Allscripts Professional EHR 9.0 and Allscripts Remote for BlackBerry smartphones. Allscripts Professional EHR 9.0 is a premier Electronic Health Record (EHR) system designed for small- and medium-sized physician groups. Allscripts Remote for BlackBerry smartphones provides physicians anywhere, anytime access to their Allscripts Electronic Health Records.
Allscripts Professional EHR 9.0 delivers a state-of-the-art graphical user interface (GUI), thereby streamlining and simplifying navigation and common tasks. It delivers new capabilities that help physicians to build patient-care teams and manage chronic diseases. Professional EHR 9.0 provides the physician a dashboard that highlights a patient’s care management plan, providing at-a-glance graphing of key health measures such as blood pressure and cholesterol.
Allscripts Remote for BlackBerry smartphones enables physicians to make critical medical decisions even when they are away from the office by delivering information on their BlackBerry smartphone. The new product establishes a direct connection between the physicians and Enterprise Electronic Health Records. Physicians can access real-time patient summary information for their decision making.
We think that the new products will be acceptable to physicians and will boost their demand, thereby increasing the company’s top-line. Libertyville, Illinois-based Allscripts Healthcare Solutions Inc. is a leading provider of clinical software and information solutions meant for physicians. In Oct 2008, the company merged with Misys Plc − a global applications software and services company − to form Allscripts-Misys Healthcare Solutions Inc.
Allscripts faces strong competition from Cerner Corporation (CERN), Quality Systems Inc. (QSII) and MedAssets Inc. (MDAS). Presently, we have a ‘Neutral’ rating on the Allscripts stock.
Read the full analyst report on “MDRX”
Read the full analyst report on “CERN”
Read the full analyst report on “QSII”
Read the full analyst report on “MDAS”
Zacks Investment Research
